Treatment and assessments
DISEASE, RECURRENCE, BREAST
Patients were randomized in a 1:1 ratio to receive olaparib 300 mg or matching placebo tablets, taken orally twice daily for 1 year. Patients were stratified according to hormone receptor status (positive or negative), timing of prior CT (NACT or ACT), and prior use of platinum-based CT (yes or no) [Following randomization, patients were assessed for disease recurrence through physical examinations and medical history every 4 weeks for 24 weeks, then every 3 months through year 2, every 6 months in years 3–5, and annually after that. Breast imaging was performed every 12 months, with other imaging investigations performed at the investigator’s discretion when symptoms, physical examination findings, or laboratory results suggested the possibility of disease recurrence [